Sign In
Buy VTGN
$0.229
-0.0108 (-4.50%)
At Close: Jul 17, 2026
Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript
06:34pm, Tuesday, 13'th Feb 2024
Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
04:20pm, Tuesday, 13'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapi
3 Penny Stocks to Buy for the Next Bull Run: February 2024
07:38am, Wednesday, 07'th Feb 2024
Entering 2024, a shift toward optimism emerges in the market, with eased monetary policies potentially opening doors for penny stocks to rebound. Savvy investors, drawn to overlooked opportunities, ma
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
08:30am, Tuesday, 06'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapi
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
09:04am, Friday, 26'th Jan 2024
Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local gov
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
09:46am, Friday, 29'th Dec 2023
Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond
06:24pm, Friday, 22'nd Dec 2023
Positive results achieved in phase 3 PALISADE-2 study for Fasedienol, a potential new treatment for social anxiety disorder. It is estimated that there are roughly 25 million people in the United Stat
Vistagen Therapeutics, Inc. (VTGN) Q2 2024 Earnings Call Transcript
10:12am, Friday, 10'th Nov 2023
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2024 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - C
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
04:43pm, Thursday, 21'st Sep 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript
05:24am, Sunday, 13'th Aug 2023
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Shawn Singh - CEO Josh Prince - SVP of Business Oper
Outperforming Biotech Pops on Shareholder Buzz
10:32am, Thursday, 10'th Aug 2023
Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Master LP has become a top shareholder with a 19.7% st
Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
03:59pm, Monday, 07'th Aug 2023
Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into penny s
2 Biotech Stocks Staging Large Swings
02:32pm, Monday, 07'th Aug 2023
Sage Therapeutics Inc (NASDAQ:SAGE) is crumbling to record lows today, down 52.2% at $17.25 at last check, earlier hitting a low of $16.69.
VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here's Why
09:58am, Monday, 07'th Aug 2023
Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren't worth it or penny stocks are a scam?
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
04:30pm, Tuesday, 27'th Jun 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua
